Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 3/20 | 0.57 |
| ▸ | GRM2 | Q14416 | 13/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.44 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2901527 | 0.94 | FADS1 (0.62) | FADS1GRM2HPGDTSHRPRSS12 | |
| SCHEMBL2911319 | 0.89 | GRM2 (0.68) | FADS1GRM2 | |
| SCHEMBL2911321 | 0.89 | GRM2 (0.68) | FADS1GRM2 | |
| SCHEMBL2915825 | 0.89 | FADS1 (0.60) | FADS1GRM2HPGDTSHRPRSS12 | |
| SCHEMBL2915828 | 0.89 | FADS1 (0.60) | FADS1GRM2HPGDTSHRPRSS12 | |
| SCHEMBL2896673 | 0.87 | FADS1 (0.56) | FADS1GRM2HPGDTSHRPRSS12 | |
| SCHEMBL2911137 | 0.87 | FADS1 (0.56) | FADS1GRM2HPGDTSHRPRSS12 | |
| SCHEMBL2896402 | 0.87 | FADS1 (0.62) | FADS1GRM2HPGDTSHRPRSS12 | |
| SCHEMBL2913770 | 0.87 | FADS1 (0.56) | FADS1GRM2HPGDTSHR | |
| SCHEMBL2913774 | 0.87 | FADS1 (0.56) | FADS1GRM2HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-7816354-B2 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2010-10-19 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | NPS PHARMACEUTICALS, INC. (US) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275966-A1 | Oxazolidinone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM2 | FADS1 4353/4885GRM2 3/4885HPGD 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.